drug
AB-1003
Phase 2updated 6mo agoby Asklepios BioPharmaceutical Inc
Phase 2community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying AB-1003
News(1)
- BridgeBio gears up for rare muscular dystrophy launch with FDA approval in sightIf approved, BridgeBio Pharma’s BBP-418—which, according to one Jefferies analyst, boasts “pretty darn compelling” data—would be the first therapy for limb-girdle muscular dystrophy. The FDA has an…biospace · 15d ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that